Use of bacteriophage to target bacterial surface structures required for virulence: a systematic search for antibiotic alternatives.
Bacteriophages (phage) that infect pathogenic bacteria often attach to surface receptors that are coincidentally required for virulence. Receptor loss or modification through mutation renders mutants both attenuated and phage resistant. Such attenuated mutants frequently have no apparent laboratory growth defects, but in the host, they fail to exhibit properties needed to produce disease such as mucosal colonization or survival within professional phagocytic cells. The connection between attenuation and phage resistance has been exploited in experimental demonstrations of phage therapy. In such experiments, phage resistant mutants that arise naturally during therapy are inconsequential because of their attenuated status. A more contemporary approach to exploiting this connection involves identifying small effector molecules, identified in high-throughput screens, that inhibit one or more of the steps needed to produce a functioning phage receptor. Since such biosynthetic steps are unique to bacteria, inhibitors can be utilized therapeutically, in lieu of antibiotics. Also, since the inhibitor is specific to a particular bacterium or group of bacteria, no off-target resistance is generated in the host's commensal bacterial population. This brief review covers examples of how mutations that confer phage resistance produce attenuation, and how this coincidental relationship can be exploited in the search for the next generation of therapeutic agents for bacterial diseases.
Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Drive, Raleigh, NC, 27607, USA. paul_orndorff@ncsu.edu.
Paul E
PE
Orndorff
D000818:Animals; D000900:Anti-Bacterial Agents / Q000096:biosynthesis / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects / Q000472:pathogenicity* / Q000821:virology*; D001424:Bacterial Infections / Q000382:microbiology; D018407:Bacterial Physiological Phenomena; D001435:Bacteriophages / Q000502:physiology*; D002462:Cell Membrane / Q000378:metabolism; D055808:Drug Discovery; D006801:Humans; D011991:Receptors, Virus / Q000378:metabolism; D014774:Virulence
D000900:Anti-Bacterial Agents; D011991:Receptors, Virus
Alternative; Antibiotic; Antivirulence factor; Attenuation; Bacteriophage; Phage; Receptor; Therapy